Will the Capital Markets Open in 2025 for Life Sciences?
By

For the past several years, life science executives and investors alike have been asking the same question: when will the capital markets fully reopen?  After a challenging 2022–2023 cycle marked by inflation, rising interest rates, and geopolitical uncertainty, many hoped 2024 would bring a meaningful rebound. Instead, the year proved…Read More

Read More
Cash Strategies for Life Sciences Delays
By

The one constant when raising financing in a life sciences company is that it takes longer than initially forecasted.  As previously shared in my colleague Patrick Nugent’s article about Life Sciences Financing Trends, it is taking twice as long to close a financing round (six months or more), and the length of time…Read More

Read More
A Quick Review of the LSI USA 2025 Conference
By

This month, FLG Partner and CFO Patrick Nugent attended the LSI USA 2025 Conference, “Emerging Medtech Summit,” in Dana Point, California. This annual event is well-represented not only by Medtech companies but also by investors and strategists, resulting in well over 1,500 attendees. “LSI proved Medtech innovations are alive and…Read More

Read More
The 2025 BioPharma & MedTech IPO Landscape
By

With Highlights from the JP Morgan Healthcare Conference To understand the current IPO landscape of BioPharma and MedTech, let’s go straight to the data: There were 15 IPOs globally in 2024; 10 in 2023, and 25 in 2022 for MedTech companies. MedTech IPO activity peaked in 2021 with 61 companies…Read More

Read More

More Posts